BioNxt Solutions Inc. (CSE:BNXT)

Market Cap	81.55M +60.1%
Revenue (ttm)	15.82K -62.3%
Net Income	-6.18M
EPS	-0.05
Shares Out	129.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,670
Average Volume	79,042
Open	0.6400
Previous Close	0.6000
Day's Range	0.6300 - 0.6400
52-Week Range	0.3800 - 1.1000
Beta	1.28
RSI	53.42
Earnings Date	Mar 26, 2026

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 20
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.